Guardant Health Announces Debt Exchange and New Notes Issuance

Details

announced that it entered into exchange agreements to retire approximately $659.3 million of its outstanding 0% Convertible Senior Notes due 2027 and issue $600 million of 1.25% Convertible Senior Notes due 2031. The exchange is expected to close on February 14, 2025. In connection with the exchange, Guardant Health intends to repurchase approximately $45 million of its common stock and the exchange agent plans to repurchase approximately $35 million of its common stock. The new notes will be convertible into Guardant Health common stock at an initial conversion rate of 16.0716 shares per $1,000 principal amount of notes.

Items reported

Exhibits (2)

About Guardant Health Inc.

Guardant Health Inc. is an innovative biotechnology company specializing in the development and commercialization of precision oncology diagnostics. This company is recognized for its groundbreaking work in non-invasive cancer detection through liquid biopsy technologies, which involve analyzing circulating tumor DNA in blood samples. Guardant Health’s primary function is to provide oncologists and researchers with critical tools and data to better understand cancer, tailor treatments, and monitor disease progression, potentially improving patient outcomes significantly. Guardant Health operates prominently in the healthcare and biotechnology sector, significantly impacting fields such as cancer research and personalized medicine. Their products and services are vital for facilitating early detection of cancer, identifying treatment options, and offering companion diagnostics for pharmaceutical developments. In the financial market, Guardant Health represents an important player within the precision medicine landscape, influencing investment within the biotechnology and healthcare sectors. Founded in 2012 and headquartered in Redwood City, California, the company continues to expand its portfolio and advance its technologies, playing a pivotal role in the fight against cancer at a global level.